본문 바로가기
KERD
논문KCI 등재

대사증후군을 가진 중증정신질환자의 장기 추적관찰 : 10년 추적연구(2011~2020)

Long Term Follow-Up of Metabolic Syndrome in Patients with Severe Mental Illness among Korean Population : A 10-Year Follow-Up Study (2011-2020)

김경민|윤현주|윤보현|시영화|차용호|정유란|김성훈|정하란|송제헌
대한생물치료정신의학회 (Korean Society Of Biological Therapies In Psychiatry)|2021.02|생물치료정신의학 (Journal of the Korean Society of Biological Therapies in Psychiatry)|제27권 제1호|pp. 12-24|DOI 10.22802/jksbtp.2021.27.1.12

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

양극성 장애조현병SchizophreniaBipolar disorder대사증후군Metabolic syndrome추적연구중증정신질환Follow-up studySevere mental illness
주제분류정신과학

초록

Objectives：This study was aimed to investigate the changes in metabolic syndrome (MetS) status and long-term impact of its components over a 10-year period in severe mental illness (SMI) patients in a national mental hospital. Methods：A total of 93 patients (schizophrenia=88, bipolar disorder=5) who met the diagnosis of Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) and participated in the MetS study in 2011 were included. MetS was defined by revised National Cholesterol Education Program-Adult Treatment Panel III (revised NCEP-ATP-III) guidelines. Results：The prevalence of MetS was significantly increased from 40.9% in 2011 to 60.2% in 2020. There were significant differences in admission status and hospitalization months, compared to the groups with and without MetS. Upon reviewing the changes over a decade, systolic blood pressure (SBP) was a significant factor in the group without MetS. In the group with MetS, SBP, waist circumference, and BMI (body mass index) were significant factors. Multiple logistic regression analysis revealed that hospitalization during follow-up periods [odds ratio (OR)=0.969, 95% confidence interval (CI): 0.948-0.991] and BMI (OR=1.426, 95% CI: 1.196-1.701) were significantly associated with MetS in subjects. Conclusion：The prevalence of MetS in patients with SMI significantly increased over time. The admission status and hospitalization were also confirmed to be the significant values of MetS.

Abstract

Objectives：This study was aimed to investigate the changes in metabolic syndrome (MetS) status and long-term impact of its components over a 10-year period in severe mental illness (SMI) patients in a national mental hospital. Methods：A total of 93 patients (schizophrenia=88, bipolar disorder=5) who met the diagnosis of Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) and participated in the MetS study in 2011 were included. MetS was defined by revised National Cholesterol Education Program-Adult Treatment Panel III (revised NCEP-ATP-III) guidelines. Results：The prevalence of MetS was significantly increased from 40.9% in 2011 to 60.2% in 2020. There were significant differences in admission status and hospitalization months, compared to the groups with and without MetS. Upon reviewing the changes over a decade, systolic blood pressure (SBP) was a significant factor in the group without MetS. In the group with MetS, SBP, waist circumference, and BMI (body mass index) were significant factors. Multiple logistic regression analysis revealed that hospitalization during follow-up periods [odds ratio (OR)=0.969, 95% confidence interval (CI): 0.948-0.991] and BMI (OR=1.426, 95% CI: 1.196-1.701) were significantly associated with MetS in subjects. Conclusion：The prevalence of MetS in patients with SMI significantly increased over time. The admission status and hospitalization were also confirmed to be the significant values of MetS.

참고문헌 (58)

  1. Saha S, "A systematic review of mortality in schizophrenia : is the differential mortality gap worsening over time", Archives of General Psychiatry, 64, pp.1123~1131 (2007)
  2. Heller T, "Benefits of support groups for families of adults with severe mental illness", Am J Orthopsychiatry, 67, pp.187~198 (1997)
  3. Lambert TJ, "Medical comorbidity in schizophrenia", Med J Aust, 178, pp.S67~70 (2003)
  4. Laursen TM, "Life expectancy and cardiovascular mortality in persons with schizophrenia", Current Opinion in Psychiatry, 25, pp.83~88 (2012)
  5. Correll CU, "Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls", World Psychiatry, 16, pp.163~180 (2017)
  6. De Hert M, "Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)", Eur Psychiatry, 24, pp.412~424 (2009)
  7. Vancampfort D, "Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia", Psychiatry Res, 207, pp.25~32 (2013)
  8. McCreadie R, "Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study", BMJ, 317, pp.784~785 (1998)
  9. Sicras-Mainar A, "Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia", Neuropsychiatr Dis Treat, 11, pp.51~57 (2015)
  10. Haupt DW, "Differential metabolic effects of antipsychotic treatments", Eur Neuropsychopharmacol, 16(Suppl 3), pp.S149~S155 (2006)
  11. Mitchell AJ, "Do deficits in cardiac care influence high mortality rates in schizophrenia? a systematic review and pooled analysis", J Psychopharmacol, 24(Suppl 4), pp.69~80 (2010)
  12. Wirshing DA, "Schizophrenia and obesity : impact of antipsychotic medications", J Clin Psychiatry, 65(Suppl 18), pp.13~26 (2004)
  13. Newcomer JW, "Antipsychotic medications : metabolic and cardiovascular risk", J Clin Psychiatry, 68(Suppl 4), pp.8~13 (2007)
  14. Mottillo S, "The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis", J Am Coll Cardiol, 56, pp.1113~1132 (2010)
  15. DeFronzo RA, "Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease", Diabetes Care, 14, pp.173~194 (1991)
  16. Gami AS, "Metabolic syndrome and risk of incident cardiovascular events and death : a systematic review and meta-analysis of longitudinal studies", Journal of the American College of Cardiology, 49, pp.403~414 (2007)
  17. Grundy SM, "Diagnosis and management of the metabolic syndrome: an American Heart Association", National Heart, Lung, and Blood Institute Scientific Statement, 2005, pp.112, 2735~2752
  18. 이화영, "조현병, 조현정동장애 외래 환자들의 대사증후군 유병률", 대한조현병학회지, 15(1), pp.39~45 (2012), 대한조현병학회
  19. Kang KD, "Prevalence of metabolic syndrome in chronic schizophrenic inpatients", J Korean Soc Biol Ther Psychiatry, 18, pp.281~289 (2012)
  20. Kim CH, "Clinical correlates of metabolic syndrome in patients with chronic schizophrenia", Schizophrenia Research, 102, pp.242~243 (2008)
  21. Vancampfort D, "Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis", World Psychiatry, 14, pp.339~347 (2015)
  22. Vancampfort D, "Metabolic syndrome and metabolic abnormalities in bipolar disorder : a meta-analysis of prevalence rates and moderators", Am J Psychiatry, 170, pp.265~274 (2013)
  23. American Diabetes Association, "Consensus development conference on antipsychotic drugs and obesity and diabetes", Diabetes Care, 27, pp.596~601 (2004)
  24. Lin CC, "Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics", J Clin Psychopharmacol, 29, pp.529~536 (2009)
  25. Morrato EH, "Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes", Diabetes Care, 32, pp.1037~ (2009)
  26. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR" (2000), American Psychiatric Association Press
  27. Alberti KG, "Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;American Heart Association; World Heart Federation;International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
  28. Alméras N, "Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics", J Clin Psychiatry, 65, pp.557~564 (2004)
  29. ECDEU assessment manual for psychopharmacology, "Guy W", US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, ~ (1976)
  30. Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
  31. Inada T, "Psychotropic dose equivalence in Japan", Psychiatry Clin Neurosci, 69, pp.440~447 (2015)
  32. Stahl SM, "Which comes first : atypical antipsychotic treatment or cardiometabolic risk", Acta Psychiatr Scand, 119, pp.171~179 (2009)
  33. "ATC/DDD Index 2020"[URL]
  34. Leucht S, "Dose equivalents for antipsychotic drugs : the DDD method", Schizophr Bull, 42(Suppl 1), pp.S90~S94 (2016)
  35. 김민현, "한국 성인에서 10년간 대사증후군 유병률과 위험요인의 변화: 국민건강영양조사(2008–2017) 자료를 이용하여", Korean Journal of Family Practice, 10(1), pp.44~52 (2020), 대한가정의학회[DOI]
  36. 노재우, "정신분열병 입원 환자에서의 대사 증후군 유병률 연구", 생물정신의학, 18(1), pp.46~54 (2011), 대한생물정신의학회
  37. Correll CU, "Balancing efficacy and safety in treatment with antipsychotics", CNS Spectrums, 12, pp.12~20 (2007)
  38. Batsis JA, "Metabolic syndrome : from global epidemiology to individualized medicine", Clin Pharmacol Ther, 82, pp.509~524 (2007)
  39. Mitchell AJ, "Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis", Schizophr Bull, 39, pp.306~318 (2013)
  40. Mao YM, "Augmentation with antidepressants in schizophrenia treatment : benefit or risk", Neuropsychiatr Dis Treat, 11, pp.701~713 (2015)
  41. Hennekens CH, "Schizophrenia and increased risks of cardiovascular disease", Am Heart J, 150, pp.1115~1121 (2005)
  42. 손미애, "복합운동 프로그램이 만성정신질환자의 비만 및 대사 증후군 인자에 미치는 효과", Journal of Korean Biological Nursing Science, 16(2), pp.105~112 (2014), 한국기초간호학회[DOI]
  43. Faulkner G, "Body mass index, waist circumference and quality of life in individuals with schizophrenia", Schizophr Res, 90, pp.174~178 (2007)
  44. Newcomer JW, "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia", Archives of General Psychiatry, 59, pp.337~345 (2002)
  45. Czobor P, "Antipsychotic-induced weight gain and therapeutic response : a differential association", J Clin Psychopharmacol, 22, pp.244~251 (2002)
  46. Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence", Eur Psychiatry, 19, pp.415~422 (2004)
  47. Goldstein BJ, "Insulin resistance : from benign to type 2diabetes mellitus", Rev Cardiovasc Med, 4(Suppl 6), pp.S3~S10 (2003)
  48. Alberti KG, "The metabolic syndrome-a new worldwide definition", Lancet, 366, pp.1059~1062 (2005)
  49. McEvoy J, "Prevalence of the metabolic syndrome in patients with schizophrenia : baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE)schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2006)
  50. De Hert MA, "Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication", Schizophr Res, 83, pp.87~93 (2006)
  51. Lieberman JA, "Comprehensive care of schizophrenia: a textbook of clinical" (2001), Martin Dunitz
  52. Patel JK, "Metabolic profiles of second-generation antipsychotics in early psychosis : findings from the CAFE study", Schizophr Res, 111, pp.9~16 (2009)
  53. McEvoy JP, "Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison", Am J Psychiatry, 164, pp.1050~1060 (2007)
  54. Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder : an open randomised clinical trial", The Lancet, 371, pp.1085~1097 (2008)
  55. Meyer JM, "Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial : prospective data from phase 1", Schizophr Res, 101, pp.273~286 (2008)
  56. Yazici MK, "The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia : findings from a cohort in Turkey", Eur Arch Psychiatry Clin Neurosci, 261, pp.69~78 (2011)
  57. Grover S, "Prevalence of metabolic syndrome in patients with schizophrenia in India", Psychiatry Res, 200, pp.1035~1037 (2012)
  58. Gordon PC, "Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia", Neuropsychiatr Dis Treat, 9, pp.133~138 (2013)

관련 논문AI추천

조현병, 조현정동장애 외래 환자들의 대사증후군 유병률이화영, 최정은대한조현병학회 · 대한조현병학회지2012 · 제15권 제1호정신분열병 입원 환자에서의 대사 증후군 유병률 연구노재우, 조애화, 조연수대한생물정신의학회 · 생물정신의학2011 · 제18권 제1호Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study권준수, 김대호, 김성완, 김재진, 김종훈, 남희정, 박일호, 안석균, 오홍석, 원승희, 유승형, 이강욱, 이규영, 이승환, 이유상, 이중서, 이중선, 주연호, 홍경수대한신경정신의학회 · PSYCHIATRY INVESTIGATION2017 · 제14권 제1호The Contribution of Abdominal Obesity and Dyslipidemia to Metabolic Syndrome in Psychiatric Patients곽미향, 김기원, 김성환, 김학진, 김홍섭, 한기훈대한내과학회 · The Korean Journal of Internal Medicine2010 · 제25권 제2호The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics강시현, 고유경, 소민아, 이종일대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2013 · 제11권 제2호Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics김세현, 이남영, Han Young You, In Won Chung, Seong Hoon Jeong, Tak Youn, Ung Gu Kang, Yong Min Ahn, Yong Sik Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2018 · 제15권 제6호

이 간행물의 다른 논문 (7건)

정신질환 연구에서의 일주기 리듬 분석정희정, 김수연, 문은수pp. 5-11지역사회 정신건강 종사자에서 소진과 이직 의도의 관계 : 보람의 매개 효과전민, 이주연, 김미나, 이유리, 김성완, 오민주, 박인후pp. 25-32알츠하이머 치매 환자에서 치료 전 중증도에 따른 약물의 장기 치료 효과박유리, 권인선, 서희원, 김정란pp. 33-39젊은 성인 남성 우울증 환자에서 ADHD 경향성에 따른 인지기능의 특징정성원, 이호준, 신소정, 김양태pp. 40-49대학생의 불면 증상 완화를 위한 모바일 중재 플랫폼 개발 연구차미영, 박성규, 안동현, 이상원pp. 50-58
원문 보기